4032 related articles for article (PubMed ID: 6238002)
1. Influence of interferon on C19-steroids in urine of malignant skin melanoma and malignant breast neoplasm patients.
Marković L; Ivanović S; Konstantinović I; Ikić D; Micić J; Stakić B
Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):416-8. PubMed ID: 6238002
[TBL] [Abstract][Full Text] [Related]
2. [Alpha 2 -interferon therapy in metastasizing malignant melanoma].
Landthaler M; Geyer C; Papendick U; Braun-Falco O
Dtsch Med Wochenschr; 1987 Jun; 112(23):919-21. PubMed ID: 3582200
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.
Krown SE; Burk MW; Kirkwood JM; Kerr D; Morton DL; Oettgen HF
Cancer Treat Rep; 1984 May; 68(5):723-6. PubMed ID: 6722830
[TBL] [Abstract][Full Text] [Related]
4. [The effect of human lymphoblastoid interferon (HLBI) on the growth of 2 human malignant melanoma xenografts in nude mice].
Hashizume S
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1296-302. PubMed ID: 6732256
[TBL] [Abstract][Full Text] [Related]
5. [Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].
Bédane C; Le Brun V; Boulinguez S; Berdah JF; Bouyssou ML; Delpuget N; Bernard P; Tubiana-Mathieu N; Bonnetblanc JM
Ann Dermatol Venereol; 1999 Feb; 126(2):142-6. PubMed ID: 10352829
[TBL] [Abstract][Full Text] [Related]
6. [Basic study on interferon-beta: Part IV. Antitumor effect on nude mouse-transplanted human tumors].
Nobuhara M; Kanamori T; Ashida Y; Horisawa Y; Harada Y; Asami T
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2117-22. PubMed ID: 3717959
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of malignant melanoma with beta-interferons].
Faulhaber G; Lechner W; Röckl H
Z Hautkr; 1988 Oct; 63(10):811-5. PubMed ID: 3239130
[TBL] [Abstract][Full Text] [Related]
8. [Local application of interferon beta to skin lesions of malignant melanoma and malignant lymphoma--clinical and histopathological analysis].
Ito Y; Jimbow K; Miura S; Maeda K
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1263-8. PubMed ID: 6732253
[TBL] [Abstract][Full Text] [Related]
9. 5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid.
Agrup G; Andersson T; Falck B; Persson K; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1975; 55(1):5-6. PubMed ID: 46673
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
[TBL] [Abstract][Full Text] [Related]
11. [Clinical effect and histopathologic observation of malignant melanoma by intratumoral administration of HuIFN- beta].
Ishihara K; Hayasaka K; Yamamoto A
Gan No Rinsho; 1983 May; 29(6):603-7. PubMed ID: 6876428
[TBL] [Abstract][Full Text] [Related]
12. [Interferon in the treatment of malignant melanoma. Results of clinical studies].
Elsässer-Beile U; Drews H
Fortschr Med; 1987 Jun; 105(21):401-3, 42. PubMed ID: 3305266
[No Abstract] [Full Text] [Related]
13. [Clinical trials of interferon-beta (MR-21) in the treatment of malignant tumors of the skin].
Kukita A
Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):977-86. PubMed ID: 3320228
[No Abstract] [Full Text] [Related]
14. [Risk factors for lymph node metastasis in malignant melanoma].
Mussack T; Waldner H; Kharraz-Tavakol A
Zentralbl Chir; 1996; 121(6):465-8. PubMed ID: 8767332
[TBL] [Abstract][Full Text] [Related]
15. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
17. Different manifestations of malignant melanoma in the breast: a report of 12 cases and a review of the literature.
Kurul S; Taş F; Büyükbabani N; Mudun A; Baykal C; Camlica H
Jpn J Clin Oncol; 2005 Apr; 35(4):202-6. PubMed ID: 15845569
[TBL] [Abstract][Full Text] [Related]
18. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
[TBL] [Abstract][Full Text] [Related]
19. Effects of human fibroblast interferon on human tumors transplanted into nude mice: sensitivity of malignant melanoma.
Hashizume S; Nagao S; Tanaka N; Sekiguchi F; Kohno M; Ogawa H; Yoshino Y; Seki K; Ishihara K
Jpn J Exp Med; 1983 Apr; 53(2):77-85. PubMed ID: 6663804
[TBL] [Abstract][Full Text] [Related]
20. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
Pappo I; Lotem M; Klein M; Orda R
Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
